Complications Post-COVID-19 and Risk Factors among Patients after Six Months of a SARS-CoV-2 Infection: A Population-Based Prospective Cohort Study

Salvador Doménech-Montoliu, Joan Puig-Barberà, Maria Rosario Pac-Sa, Paula Vidal-Utrillas, Marta Latorre-Poveda, Alba Del Río-González, Sara Ferrando-Rubert, Gema Ferrer-Abad, Manuel Sánchez-Urbano, Laura Aparisi-Esteve, Gema Badenes-Marques, Belen Cervera-Ferrer, Ursula Clerig-Arnau, Claudia Dols-Bernad, Maria Fontal-Carcel, Lorna Gomez-Lanas, David Jovani-Sales, Maria Carmen León-Domingo, Maria Dolores Llopico-Vilanova, Mercedes Moros-Blasco, Cristina Notari-Rodríguez, Raquel Ruiz-Puig, Sonia Valls-López and Alberto Arnedo-Pena

Abstract: In October 2020, we conducted a population-based prospective cohort study to determine post-COVID-19 complications, recovery, return to usual health, and associated risk factors in 536 cases of COVID-19 outbreak in Borriana (Spain) by administering an epidemiological questionnaire via phone interviews. A total of 484 patients participated (90.3%), age mean 37.2 years, and 301 females (62.2%). Mild illness was the most common COVID-19 manifestation. After six months, 160 patients (33.1%) suffered at least one complication post-COVID-19, and 47 (29.4%) of them sought medical assistance. The most frequent persistent symptoms were hair loss, fatigue, loss of smell or taste, and headache. Risk factors associated with a complication were female sex (adjusted relative risk, [aRR] = 1.93 95% confidence interval [CI] 1.41–2.65), age 35 years and above (aRR = 1.50 95% CI 1.11–2.00), and at least a COVID-19 exposure (aRR = 2.13 95% CI 1.11–4.09). Male sex, age younger than 35 years, and low COVID-19 exposures were associated with better recovery and return to usual health. A third of patients presented persistent symptoms compatible with the long-COVID-19 syndrome. In conclusion, an active medical follow-up of post-COVID-19 patients must be implemented.

Keywords: COVID-19; incidence; complications; symptoms; recovery; health; risk factors; exposure; cohort; prospective; population-based

1. Introduction

After more than year of the COVID-19 pandemic, many aspects of this new and complicated disease are still poorly understood and characterized [1,2], such as the frequency...
and risk factors associated with complications or sequelae after acute COVID-19 illness. Additionally, it is not clear what should be considered a long-COVID-19 or post-COVID-19 syndrome (LCS) [3–5]. Currently, post-COVID-19 syndrome is defined by persistent clinical signs and symptoms that appear while or after suffering COVID-19 for more than 12 weeks and that cannot be explained by an alternative diagnosis [6–9]. The syndrome includes affection of respiratory, cardiovascular, neurological, gastrointestinal, musculoskeletal systems, psychiatric/psychological issues, ear, nose, throat, and dermatological symptoms, and general status impairment [4–7,10–12]. However, it is controversial whether LCS should be considered a post-infectious syndrome rather than a singular syndrome in the evolution of the disease [13]. To avoid controversies, recent research focuses on LCS consensus definition [14], and underlines the prolonged effects of post-acute COVID-19 symptomatology and organ dysfunction [15,16], included a post-infectious myalgic encephalomyelitis/chronic fatigue syndrome which could happen after viral diseases [17,18].

The frequency of complications subsequent to the acute phase has important variations in the ranges from 10% to 93% [3,5,8,19–25]. The studies of post-COVID-19 complications are heterogeneous; including hospitalized versus non-hospitalized patients, with variable demographic characteristics of patients, the severity of the disease, follow-up time, different measures of the complications, control groups for comparison, designs, sample size, and statistical analysis [5,21,26–29]. In this situation, accruing evidence on the frequency and the manifestation of LCS and related risk factors is needed [22,30,31].

Our aim was to describe post-COVID-19 complications, recovery, and return to the usual state of health in a cohort of patients that suffered a SARS-CoV-2 infection and estimate the strength of the association of diverse risk factors with LCS.

2. Materials and Methods

2.1. Explanation

In March 2020 a COVID-19 outbreak took place during the mass gathering events (MGEs) of the Falles festival in Borriana, a city of 34,000 inhabitants, in the Castellon province, Valencia Community (Spain), with 536 laboratory-confirmed cases of COVID-19 [32]. In October 2020 a population-based prospective cohort study of 536 COVID-19 patients was performed by the Public Health Center of Castellón de la Plana, and the Emergency and Microbiology and Clinical Analysis Services of Hospital de la Plana Vila-real [33].

We first performed a sero-survey and an epidemiological questionnaire survey in June 2020 that has been described by Domenech-Montoliu and co-authors [32]. A second sero-survey and questionnaire were run in October 2020. In summary, the sero-surveys included determinations of anti-SARS-CoV-2 N-antibodies in June and October 2020 with a flow chart of the study, and ABO blood groups and vitamin D status in October 2020. The sero-survey results were subject of two previous publications [33,34], and are no further discussed in the current manuscript. Health staff of Hospital La Plana Vila-real, and several health centers (Borriana, Vila-real, Onda, and Vall D’Uixo) performed the telephone interviews. In June 2020, we collected information about acute COVID-19 illness (symptoms, medical consultation, health status), demographic data (age, sex), lifestyle (smoking habit, alcohol consumption, physical exercise), body mass index (BMI = kg/m², obesity ≥ 30.0), occupation as a proxy social class, COVID-19 exposure (measured as positive observation a person coughing at the MGEs, contact with a COVID-19 patient or a relative with COVID-19, attendance two or more MGEs). In the second (October 2020) telephone survey, we collected information on the evolution of the COVID-19 disease, complications, persistent symptoms, health recovery, return to the usual state of health, and medical consultation after the acute phase.

2.2. Statistical Methods

We performed the statistical analysis and considered complications, recovery, and return to the usual state of health as dependent variables; age, sex, ABO blood groups, oc-
ocupation, chronic disease, lifestyle, BMI, COVID-19 exposure during the MGEs, symptoms, and medical consultation of acute COVID-19 illness were independent variables.

In the univariate analysis, Chi2 and Fisher exact tests were used to compare qualitative variables and the Kruskal-Wallis test for quantitative variables. The incidence rate (IR) of a variable was obtained dividing the positive cases of this variable by the exposed population, and the relative risk (RR) of each independent variable, dividing the IR of the population exposed by the IR of the population no-exposed of this variable, with a 95% confidence interval (CI). After a revision of medical literature, we employed directed acyclic graphs (DAGs) [35], and the program DAGitty 3.0 version (Johannes Textor, Nijmegen, The Netherlands) [36,37] to define the potential confounders of each independent variable. We used inverse probability weighted regression [38] in the multivariable analysis to estimate adjusted incidence rates (aIR) and adjusted relative risks (aRR). We applied Stata® 14.2 version (Stata Corp, College Station, TX, USA) or all calculations.

The study was part of public health surveillance activities of the COVID-19 outbreak control measures in the MGEs of the Falles festival [32], and it was exempt from the Ethics Review Board approval’s protocol according to the Spanish legislation and regulations [39–42]. The study was approved by the director of the Public Health Center of Castelló de la Plana and the management of the Health Department of la Plana. All participants or the parents of minors provided the informed written consent to be included in the study.

3. Results

A total of 484 patients participated in the study with a response rate of 90.3% from the 536 COVID-19 laboratory-confirmed cases in MEGs. The mean ± standard deviation (SD) age of participants was 37.2 ± 17.1 (range 1–81) years, and 301 were females (62.2%). In the outbreak, a death attributable to COVID-19 was reported, 13 patients required hospitalization, and mild illness was the most frequent clinical presentation.

Patients’ characteristics and potential risk factors of complications of the COVID-19 illness, health recovery, and return to the usual health before the acute illness in the six months of follow-up are shown in Table 1. A total of 160 participants reported at least one post-COVID-19 complication (33.1%), 47 (29.4%) of them sought medical care, but no hospitalizations took place. An 81.8% of the participants recovered, and 83.2% returned to their usual state of health before the COVID-19 episode. Complications were more frequent in females, elder age, B blood group, current smoking status, high COVID-19 exposure, and those who reported symptomatic acute COVID-19 episode, and sought medical care. Health recovery and return to the usual health were highest in males, young individuals, attendance of MEGs less than two events, asymptomatic acute illness, and fewer medical consultations.

Table 1. Incidence rate (IR) of complications, health recovery, and return to the usual health. Borriana COVID-19 cohort 2020.
Table 1. Cont.

| Variables                        | Total        | Complications | Health Recovery | Return to the Usual Health |
|----------------------------------|--------------|---------------|-----------------|----------------------------|
|                                  | N (%)        | N IR (%)      | N IR (%)        | N IR (%)                   |
| ABO blood group                  |              |               |                 |                            |
| O                                | 200 (41.1)   | 63 (31.5)     | 166 (83.0)      | 173 (86.5)                 |
| A                                | 220 (45.6)   | 70 (31.8)     | 179 (81.4)      | 178 (80.9)                 |
| B                                | 44 (9.1)     | 22 (50.0)     | 31 (72.1)       | 32 (74.4)                  |
| AB                               | 19 (3.9)     | 4 (21.1)      | 19 (100.0)      | 19 (100.0)                 |
| Occupations                      |              |               |                 |                            |
| I–II                             | 145 (30.2)   | 48 (33.1)     | 123 (84.8)      | 125 (86.2)                 |
| III–VI                           | 336 (69.9)   | 112 (33.3)    | 269 (80.3)      | 274 (81.8)                 |
| Chronic disease                  |              |               |                 |                            |
| No-smoking                       | 297 (63.5)   | 98 (33.0)     | 249 (84.1)      | 252 (85.1)                 |
| Ex-smoking                       | 106 (22.7)   | 36 (34.0)     | 80 (75.5)       | 80 (75.5)                  |
| Current smoking                  | 65 (13.9)    | 23 (35.4)     | 51 (78.5)       | 56 (86.2)                  |
| Alcohol consumption              |              |               |                 |                            |
| Physical exercise                | 289 (59.7)   | 95 (32.9)     | 236 (81.9)      | 243 (84.4)                 |
| Body Mass Index (BMI) (kg/m²)    |              |               |                 |                            |
| <18.5                            | 41 (8.6)     | 6 (14.6)      | 40 (97.7)       | 41 (100.0)                 |
| 18.5–24.9                        | 210 (43.8)   | 82 (39.1)     | 165 (78.6)      | 171 (81.4)                 |
| 25.0–29.9                        | 148 (30.9)   | 48 (32.4)     | 123 (83.7)      | 120 (81.6)                 |
| ≥30.0                            | 80 (16.7)    | 23 (28.8)     | 63 (78.7)       | 66 (82.5)                  |
| Observed a person with a cough at MGEs | 203 (42.5) | 78 (38.0) | 166 (81.0) | 165 (80.5) |
| Contact with COVID-19 patient    | 390 (81.8)   | 138 (35.4)    | 314 (80.7)      | 316 (81.2)                 |
| Family with COVID-19 patient     | 303 (62.7)   | 110 (36.3)    | 243 (80.5)      | 246 (81.5)                 |
| Attendance MGEs ≥ 2             | 295 (61.0)   | 115 (39.0)    | 228 (77.6)      | 235 (79.9)                 |
| At least a COVID-19 exposure     | 455 (94.0)   | 155 (34.1)    | 370 (81.5)      | 375 (82.6)                 |
| Symptomatic patients of COVID-19 illness | 430 (88.8) | 155 (34.1) | 344 (80.0) | 350 (81.4) |
| Asymptomatic patients           | 54 (11.2)    | 5 (9.3)       | 51 (94.4)       | 52 (96.3)                  |
| Medical consultation of acute COVID-19 illness | 208 (43.0) | 106 (51.0) | 147 (71.0) | 150 (72.5) |
| Medical care post-COVID-19 periode | 47 (9.8) | 47 (100.0) | 19 (40.4) | 20 (42.6) |

1 IR, Incidence rate; 2 Missing information 1 participant; 3 Missing information 1 participant; 4 Missing information 1 participant; 5 Occupation groups I–II professional, managerial, and technical occupations; groups III–VI: skilled, no-manual or manual, partly skilled, unskilled occupations; 6 Missing information 3 participants; 7 Missing information 4 participants; 8 Missing information 16 participants; 9 Missing information 14 participants; 10 Missing information 5 participants; 11 MGEs, mass gathering events; 12 Missing information 6 participants; 13 Missing information 7 participants; 14 Missing information 1 participant; 15 Summary all exposures; 16 Missing information 5 participants.

We show persistent post-COVID-19 symptoms by sex and four age groups in Table 2. The most frequent signs or symptoms were hair loss (24.8%), fatigue (17.4%) loss of smell or taste (16.1%), headache (15.1%) muscle pain (11.8%), insomnia (11.8%), anxiety (9.1%), weakness (8.5%), restlessness (8.1%), hands and foot’s pain (7.4), and dyspnea (6.8%). Females reported suffering more symptoms than males, especially hair loss (35.9% versus 6.5% p = 0.000), fatigue (21.9% versus 9.8% p = 0.000), and loss of smell or taste (21.6% versus 7.1% p = 0.000).
### Table 2. Reported persistent post-COVID-19 symptoms of participants by sex and age. Borriana COVID-19 cohort 2020.

| Persistent Symptoms       | Male N = 183 | Female N = 301 | Total N = 484 | p-Value | Age-Groups (Years) | p-Value |
|---------------------------|--------------|----------------|---------------|---------|--------------------|---------|
|                           | N (%)        | N (%)          | N (%)         |         | 0–14               |         |
| **Total**                 |              |                |               |         |                    |         |
| Fatigue                   | 18 (9.8)     | 66 (21.9)      | 84 (17.4)     | 0.007   |                    |         |
| Weakness                  | 11 (6.0)     | 30 (10.0)      | 41 (8.5)      | 0.177   |                    |         |
| Dyspnea                   | 12 (6.6)     | 21 (7.0)       | 33 (6.8)      | 1.000   |                    |         |
| Thorax oppression         | 5 (2.7)      | 13 (4.3)       | 18 (3.7)      | 0.463   |                    |         |
| Cough                     | 10 (5.5)     | 17 (5.7)       | 27 (5.6)      | 1.000   |                    |         |
| Fever                     | 0 (0)        | 5 (1.7)        | 5 (1.0)       | 0.162   |                    |         |
| Throat pain               | 5 (2.7)      | 23 (7.6)       | 28 (5.8)      | 0.027   |                    |         |
| Runny nose                | 15 (8.2)     | 22 (7.3)       | 37 (7.6)      | 0.727   |                    |         |
| Loss of smell/taste       | 13 (7.1)     | 65 (21.6)      | 78 (16.1)     | 0.000   |                    |         |
| Nausea/vomits             | 3 (1.6)      | 4 (1.3)        | 7 (1.4)       | 1.000   |                    |         |
| Diarrhea                  | 11 (6.0)     | 10 (3.3)       | 21 (4.3)      | 0.173   |                    |         |
| **Alimentary intolerance**|              |                |               |         |                    |         |
| Abdominal pain            | 6 (3.3)      | 14 (4.7)       | 20 (4.1)      | 0.839   |                    |         |
| Muscle pain               | 13 (7.1)     | 44 (14.6)      | 57 (11.8)     | 0.013   |                    |         |
| Headache                  | 18 (9.8)     | 55 (18.3)      | 73 (15.1)     | 0.013   |                    |         |
| Hands/foots pain          | 5 (2.7)      | 31 (10.3)      | 36 (7.4)      | 0.002   |                    |         |
| Dizziness                 | 6 (3.3)      | 16 (5.3)       | 22 (4.5)      | 0.371   |                    |         |
| Ringing ears              | 8 (4.4)      | 15 (5.0)       | 23 (4.8)      | 0.829   |                    |         |
| Disorder vision           | 5 (2.7)      | 13 (4.3)       | 18 (3.7)      | 0.463   |                    |         |
| Insomnia                  | 15 (8.2)     | 42 (14.0)      | 57 (11.8)     | 0.060   |                    |         |
| Night sweats              | 5 (2.7)      | 24 (8.0)       | 29 (6.0)      | 0.018   |                    |         |
| Depression                | 3 (1.6)      | 12 (4.0)       | 15 (3.1)      | 0.183   |                    |         |
| Restlessness              | 7 (3.8)      | 32 (10.6)      | 39 (8.1)      | 0.009   |                    |         |
| Difficulty concentration  | 4 (2.2)      | 16 (5.3)       | 20 (4.1)      | 0.104   |                    |         |
| Anxiety                   | 9 (4.9)      | 35 (11.6)      | 44 (9.1)      | 0.014   |                    |         |
| Mental confusion          | 2 (1.1)      | 14 (4.7)       | 16 (3.3)      | 0.037   |                    |         |
| Difficulty articulating words | 1 (0.6) | 5 (1.7)       | 6 (1.2)       | 0.416   |                    |         |
| Difficulty to solve math operations | 1 (0.6) | 3 (1.0)       | 4 (0.8)       | 1.000   |                    |         |
| Skin’s lesions            | 9 (4.9)      | 16 (5.3)       | 25 (5.2)      | 0.000   |                    |         |
| Loss hair                 | 12 (6.5)     | 108 (36.0)     | 120 (24.8)    | 0.000   |                    |         |

The mean (±SD) duration of persistent post-COVID-19 symptoms was 160.9 ± 45.5 days (range 3–280 days). The mean (±SD) duration in females was 162.6 ± 44.5 (range 3–280) days, and in males 155.8 ± 48.8 (range 15–210) days without significant difference (p = 0.444).

Patients 65 years old and older reported more symptoms, with the exception of loss of smell or taste and the hair loss, which were more common in subjects in the range of 15–34 years and 35–64 years. In subjects 65 years and older, the most frequently reported symptoms were fatigue (41.2%), hand/foot pain (29.4%), and insomnia (29.4%).

The mean duration of post-COVID-19 symptoms was 157.5 ± 45.0 days, 163.3 ± 53.9 days, 160.6 ± 42.3 days, and 154.3 ± 43.9 days for subjects aged 0–14, 15–34, 35–64, and 65 and above, with p > 0.05 for the difference.

Considering the aIR of acute COVID-19 symptoms and the occurrence of complications (Table 3), many of acute symptoms were predictive of complications, highlighting: weakness (aRR = 2.25 95% CI 1.62–3.13), fever (aRR = 1.79 95% CI 1.35–2.38), loss of smell or taste (aRR = 1.47 95% CI 1.11–1.94), headache (aRR = 1.53 95% CI 0.78–1.99), myalgia (aRR = 1.50 95% CI 1.13–1.99), dyspnea (aRR = 1.61 95% CI 1.00–2.59), and skin’s lesions (aRR = 1.84 95% CI 1.41–2.40). Symptomatic patients presented an elevated risk of compli-
cations versus asymptomatic patients (aRR = 4.60 95% CI 2.05–10.3), and 5 acute symptoms and above were associated with a high risk of complications (aRR = 1.80 95% CI 1.37–2.36). Medical consultation increased the risk of complications (aRR = 2.61 95% CI 1.95–3.50).

Table 3. Symptoms of acute COVID-19 illness and complications by adjusted incidence rate (aIR) and adjusted relative risk (aRR). Borribana COVID-19 cohort 2020.

| Symptoms                  | Complications | aIR (%) | aRR (95% CI) | p-Value |
|---------------------------|----------------|---------|--------------|---------|
| Cough                     | Yes            | 38.2    | 1.27 (0.98–1.63) | 0.067   |
|                           | No             | 30.2    | 1.00         |         |
| Runny nose                | Yes            | 34.3    | 1.05 (0.79–1.38) | 0.756   |
|                           | No             | 32.8    | 1.00         |         |
| Throat pain               | Yes            | 37.5    | 1.17 (0.89–1.52) | 0.255   |
|                           | No             | 32.1    | 1.00         |         |
| Fever                     | Yes            | 40.7    | 1.79 (1.35–2.38) | 0.000   |
|                           | No             | 22.7    | 1.00         |         |
| Loss of smell/taste       | Yes            | 39.0    | 1.47 (1.11–1.94) | 0.006   |
|                           | No             | 26.6    | 1.00         |         |
| Diarrhea                  | Yes            | 38.5    | 1.26 (0.96–1.67) | 0.094   |
|                           | No             | 30.5    | 1.00         |         |
| Vomits                    | Yes            | 44.7    | 1.38 (0.91–2.08) | 0.128   |
|                           | No             | 32.5    | 1.00         |         |
| Weakness                  | Yes            | 41.1    | 2.25 (1.62–3.13) | 0.000   |
|                           | No             | 8.3     | 1.00         |         |
| Headache                  | Yes            | 40.7    | 1.53 (1.78–1.99) | 0.002   |
|                           | No             | 26.6    | 1.00         |         |
| Myalgia                   | Yes            | 39.7    | 1.50 (1.13–1.99) | 0.005   |
|                           | No             | 26.4    | 1.00         |         |
| Dyspnea                   | Yes            | 61.2    | 1.61 (1.00–2.59) | 0.048   |
|                           | No             | 47.7    | 1.00         |         |
| Skin's lesions            | Yes            | 58.0    | 1.84 (1.41–2.40) | 0.000   |
|                           | No             | 31.5    | 1.00         |         |
| Number of symptoms ≥ 5   | Yes            | 43.8    | 1.80 (1.37–2.36) | 0.000   |
|                           | No             | 24.3    | 1.00         |         |
| Asymptomatic              | Yes            | 7.6     | 1.00         |         |
|                           | No             | 34.9    | 4.60 (2.05–10.3) | 0.000   |
| Medical consultation      | Yes            | 51.1    | 2.61 (1.95–3.50) | 0.000   |
|                           | No             | 19.5    | 1.00         |         |

1 Adjusted for age, sex, ABO blood groups, COVID-19 exposures, lifestyle, obesity (body mass index ≥ 30), occupation, chronic disease.

Symptoms of acute illness and health recovery are shown in Table 4. Not to report dyspnea was associated with recovery (aRR = 1.81 95% CI 1.10–2.99). The absence of loss of smell or taste (aRR = 1.13 95% CI 1.03–1.24), weakness (aRR = 1.12 95% CI 1.02–1.22),
headache (aRR = 1.10 95% CI 1.01–1.21), and less than five acute symptoms were associated with recovery (aRR = 1.15 95% CI 1.04–1.27). Not to report medical consultations was associated with recovery (aRR = 1.28 95% CI 1.15–1.42).

Table 4. Symptoms of acute COVID-19 illness and health recovery by adjusted incidence rate (aIR) and adjusted relative risk (aRR). Borriana COVID-19 cohort 2020.

| Symptoms             | Health Recovery | aRR 1 (95% CI) | Total (%) | p-Value |
|----------------------|-----------------|----------------|-----------|---------|
|                      | aIR 1 (%)       |                |           |         |
| Cough                |                 |                |           |         |
| Yes                  | 79.1            | 1.0            |           |         |
| No                   | 83.5            | 1.06 (0.97–1.15) | 0.237    |         |
| Runny nose           |                 |                |           |         |
| Yes                  | 80.6            | 1.0            |           |         |
| No                   | 83.4            | 1.04 (0.94–1.14) | 0.481    |         |
| Throat pain          |                 |                |           |         |
| Yes                  | 85.3            | 1.0            |           |         |
| No                   | 79.9            | 0.94 (0.86–1.04) | 0.148    |         |
| Fever                |                 |                |           |         |
| Yes                  | 79.2            | 1.0            |           |         |
| No                   | 84.8            | 1.07 (0.98–1.17) | 0.123    |         |
| Loss of smell/taste  |                 |                |           |         |
| Yes                  | 76.8            | 1.0            |           |         |
| No                   | 86.9            | 1.13 (1.03–1.24) | 0.007    |         |
| Diarrhea             |                 |                |           |         |
| Yes                  | 77.8            | 1.0            |           |         |
| No                   | 83.8            | 1.08 (0.96–1.20) | 0.184    |         |
| Vomits               |                 |                |           |         |
| Yes                  | 69.2            | 1.0            |           |         |
| No                   | 82.7            | 1.20 (0.95–1.50) | 0.127    |         |
| Weakness             |                 |                |           |         |
| Yes                  | 78.7            | 1.0            |           |         |
| No                   | 88.1            | 1.12 (1.02–1.22) | 0.012    |         |
| Headache             |                 |                |           |         |
| Yes                  | 77.7            | 1.0            |           |         |
| No                   | 85.7            | 1.10 (1.01–1.21) | 0.035    |         |
| Myalgia              |                 |                |           |         |
| Yes                  | 80.2            | 1.0            |           |         |
| No                   | 82.6            | 1.03 (0.94–1.13) | 0.539    |         |
| Dyspnea              |                 |                |           |         |
| Yes                  | 41.8            | 1.0            |           |         |
| No                   | 75.8            | 1.81 (1.10–2.99) | 0.020    |         |
| Skin’s lesions       |                 |                |           |         |
| Yes                  | 76.2            | 1.0            |           |         |
| No                   | 82.5            | 1.08 (0.94–1.25) | 0.265    |         |
| Number of symptoms ≥ 5 |                |                |           |         |
| Yes                  | 75.6            | 1.0            |           |         |
| No                   | 86.8            | 1.15 (1.04–1.27) | 0.006    |         |
| Asymptomatic         |                 |                |           |         |
| Yes                  | 82.9            | 1.0            |           |         |
| No                   | 81.0            | 0.98 (0.94–1.11) | 0.576    |         |
| Medical consultation |                 |                |           |         |
| Yes                  | 69.9            | 1.0            |           |         |
| No                   | 89.6            | 1.28 (1.15–1.42) | 0.000    |         |

1 Adjusted for age, sex, ABO blood groups, COVID-19 exposures, lifestyle, obesity (body mass index ≥ 30), occupation, and chronic disease.

The absence of weakness during the acute illness was associated with return to the usual health (aRR = 1.15 95% CI 1.6–1.20) Table 5. The absence of loss of smell or taste (aRR = 1.10 95% CI 1.01–1.1), headache (aRR = 1.10 95% CI 1.01–1.20), less than 5 acute
illness symptoms were associated with increased return to the usual health (aRR = 1.13 95% CI 1.03–1.24), as was the absence of medical consultation (aRR = 1.22 95% CI 1.12–1.35).

Table 5. Symptoms of acute COVID-19 illness and return to the usual health by adjusted incidence ratio (aIR) and adjusted relative risk (aRR). Borriana COVID-19 cohort 2020.

| Symptoms               | Return to the Usual Health | Total (%) |
|------------------------|----------------------------|-----------|
|                        | aIR (%) (95% CI)           | p-Value   |
| Cough                  |                            |           |
| Yes                    | 81.7 (1.00)                |           |
| No                     | 83.9 (1.03 (0.94–1.12))    | 0.528     |
| Runny nose             |                            |           |
| Yes                    | 82.0 (1.00)                |           |
| No                     | 84.5 (1.03 (0.94–1.13))    | 0.499     |
| Throat pain            |                            |           |
| Yes                    | 82.2 (1.00)                |           |
| No                     | 85.3 (1.03 (0.89–1.05))    | 0.438     |
| Fever                  |                            |           |
| Yes                    | 79.8 (1.00)                |           |
| No                     | 85.3 (1.07 (0.98–1.16))    | 0.142     |
| Loss smell/taste       |                            |           |
| Yes                    | 79.5 (1.00)                |           |
| No                     | 87.1 (1.10 (1.01–1.19))    | 0.031     |
| Diarrhea               |                            |           |
| Yes                    | 79.4 (1.00)                |           |
| No                     | 84.8 (1.07 (0.97–1.18))    | 0.196     |
| Vomits                 |                            |           |
| Yes                    | 86.3 (1.00)                |           |
| No                     | 83.4 (1.03 (0.88–1.06))    | 0.487     |
| Weakness               |                            |           |
| Yes                    | 78.3 (1.00)                |           |
| No                     | 90.2 (1.15 (1.06–1.26))    | 0.001     |
| Headache               |                            |           |
| Yes                    | 79.0 (1.00)                |           |
| No                     | 87.1 (1.10 (1.01–1.20))    | 0.025     |
| Myalgia                |                            |           |
| Yes                    | 79.0 (1.00)                |           |
| No                     | 85.2 (1.07 (0.98–1.19))    | 0.112     |
| Dyspnea                |                            |           |
| Yes                    | 73.4 (1.00)                |           |
| No                     | 79.3 (1.08 (0.68–1.71))    | 0.794     |
| Skin’s lesions         |                            |           |
| Yes                    | 72.3 (1.00)                |           |
| No                     | 84.4 (1.17 (0.99–1.37))    | 0.061     |
| Number of symptoms ≥ 5 |                            |           |
| Yes                    | 77.2 (1.00)                |           |
| No                     | 87.1 (1.13 (1.03–1.24))    | 0.013     |
| Asymptomatic           |                            |           |
| Yes                    | 87.7 (1.00)                |           |
| No                     | 82.2 (1.08 (0.97–1.19))    | 0.133     |
| Medical consultation   |                            |           |
| Yes                    | 73.9 (1.00)                |           |
| No                     | 90.9 (1.22 (1.12–1.35))    | 0.000     |

1 Adjusted for age, sex, ABO blood groups, COVID-19 exposures, lifestyle, obesity (body mass index ≥ 30), occupation, chronic disease.

In the adjusted multivariable analysis (Table 6), risk factors associated with a complication were female sex (aRR = 1.93 95% CI 1.41–2.65), age-group 35 years and above (aRR = 1.50 95% CI 1.14–1.99), B blood group versus O blood group (aRR = 1.51 95% CI 1.04–2.16), and current smokers versus ex-smokers (aRR = 1.61 95% CI 1.02–2.54). Three of five measures of COVID-19 exposure presented a high risk of complications: observe a per-
son with a cough at MGEs (aRR = 1.38 95% CI 1.05–1.81), attendance MGEs ≥ 2 (aRR = 1.42 95% CI 1.04–1.94), and at least a COVID-19 exposure (aRR = 2.13 95% CI 1.11–4.09).

**Table 6.** Complications, risk factors, adjusted incidence ratio (aIR) and adjusted relative risk (aRR). Borriana COVID-19 cohort 2020.

| Variables                              | Complications | aRR (95% CI)       | p Value |
|----------------------------------------|---------------|--------------------|---------|
| Sex                                    |               |                    |         |
| Female                                 | 40.6          | 1.93 (1.41–2.65)   | 0.000   |
| Male                                   | 21.0          | 1.00               |         |
| Age-groups (years)                     |               |                    |         |
| 0–34                                   | 25.8          | 1.00               | 0.004   |
| 35 and above                           | 38.7          | 1.50 (1.14–1.99)   |         |
| ABO blood group                         |               |                    |         |
| O                                      | 31.2          | 1.00               | -       |
| A                                      | 32.2          | 1.03 (0.79–1.36)   | 0.816   |
| B                                      | 46.9          | 1.51 (1.04–2.16)   | 0.026   |
| AB                                     | 23.6          | 0.76 (0.31–1.86)   | 0.545   |
| Occupations                            |               |                    |         |
| I–II                                   | 33.8          | 1.02 (0.78–1.33)   | 0.859   |
| III–VI                                 | 33.0          | 1.00               |         |
| Chronic disease                        |               |                    |         |
| Yes                                    | 35.8          | 1.12 (0.85–1.49)   | 0.416   |
| No                                     | 31.9          | 1.00               |         |
| No-smoking                             |               |                    |         |
| Yes                                    | 33.8          | 1.33 (0.88–2.02)   | 0.173   |
| No                                     | 25.3          | 1.00               |         |
| Ex-smoking                             |               |                    |         |
| Current smoking                        |               |                    |         |
| Yes                                    | 40.7          | 1.61 (1.02–2.54)   | 0.041   |
| No                                     | 32.3          | 1.00               |         |
| Alcohol consumption                    |               |                    |         |
| Yes                                    | 32.4          | 0.96 (0.70–1.32)   | 0.818   |
| No                                     | 33.6          | 1.00               |         |
| Physical exercise                      |               |                    |         |
| Yes                                    | 34.8          | 1.06 (0.73–1.22)   | 0.650   |
| No                                     | 32.8          | 1.00               |         |
| Body Mass Index (BMI) (kg/m^2)         |               |                    |         |
| BMI ≥ 30.0 (Obesity)                   | 36.7          | 1.12 (0.74–1.48)   | 0.781   |
| BMI < 30                               | 34.9          | 1.00               |         |
| COVID-19 exposure                      |               |                    |         |
| Observe a person with a cough at MGEs  |               |                    |         |
| Yes                                    | 41.7          | 1.38 (1.05–1.81)   | 0.022   |
| No                                     | 30.2          | 1.00               |         |
| Contact with COVID-19 patient          |               |                    |         |
| Yes                                    | 34.2          | 1.06 (0.71–1.60)   | 0.767   |
| No                                     | 32.3          | 1.00               |         |
| Family with COVID-19 patient           |               |                    |         |
| Yes                                    | 35.5          | 1.19 (0.91–1.55)   | 0.204   |
| No                                     | 29.9          | 1.00               |         |
| Attendance MGEs ≥ 2                    |               |                    |         |
| Yes                                    | 36.4          | 1.42 (1.04–1.94)   | 0.003   |
| No                                     | 25.6          | 1.00               |         |
Table 6. Cont.

| Variables | Complications | aIR (%) | aRR (95% CI) | p Value |
|-----------|---------------|---------|--------------|---------|
| At least a COVID-19 exposure | | | | |
| Yes | 34.3 | 2.13 (1.11–4.09) | 0.023 |
| No | 16.1 | | | |

CI, confidence interval; Adjusted for age sex ABO blood group; Adjusted for age ABO blood group occupation lifestyle obesity.

Considering health recovery after the acute illness (Table 7), younger age than 35 years (aRR = 1.15 95% CI 1.06–1.25), and male sex (aRR = 1.09 95% CI 1.00–1.19) were associated with more recovery (Table 7). The AB blood group subjects reported 100% recovery. Attendance with less than two MGEs was associated with more recovery (aRR = 1.11 95% CI 1.02–1.21).

Table 7. Health recovery, risk factors, adjusted incidence ratio (aIR) and adjusted relative risk (aRR). Borriana COVID-19 cohort 2020.

| Variables | Health Recovery | aIR (%) | aRR (95% CI) | p-Value |
|-----------|----------------|---------|--------------|---------|
| Sex | | | | |
| Female | 78.7 | 1.00 | | |
| Male | 85.8 | 1.09 (1.00–1.19) | 0.046 | |
| Age-groups (years) | | | | |
| 0–34 | 87.7 | 1.15 (1.06–1.25) | 0.001 | |
| 35 and above | 76.3 | 1.00 | | |
| ABO blood group | | | | |
| O | 83.0 | 1.00 | | |
| A | 81.6 | 1.12 (0.94–1.33) | 0.211 | |
| B | 74.3 | 1.10 (0.92–1.31) | 0.301 | |
| AB | 100.0 | 1.35 (1.14–1.58) | 0.000 | |
| Occupations | | | | |
| I–II | 84.6 | 1.06 (0.97–1.15) | 0.245 | |
| III–VI | 80.4 | 1.00 | | |
| Chronic disease | | | | |
| Yes | 80.1 | 1.00 | | |
| No | 84.0 | 1.05 (0.96–1.15) | 0.286 | |
| No-smoking | 83.4 | 1.02 (0.91–1.15) | 0.686 | |
| Ex-smoking | 81.5 | 1.00 | | |
| Current smoking | 78.4 | 1.04 (0.82–1.13) | 0.634 | |
| Alcohol consumption | | | | |
| Yes | 78.7 | 1.00 | | |
| No | 82.5 | 1.04 (0.94–1.17) | 0.406 | |
| Physical exercise | | | | |
| Yes | 80.2 | 1.00 | | |
| No | 82.2 | 1.03 (0.94–1.12) | 0.518 | |
The return to the usual health was associated with male sex (aRR = 1.11 95% CI 1.02–1.20), and age 0–34 years (aRR = 1.14 95% CI 1.05–1.24), no contact with a COVID-19 patient (aRR = 1.15 95% CI 1.06–1.25), and AB blood group (aRR = 1.15 95% CI 1.09–1.21) (Table 8).

Table 8. Return to the usual health, risk factors, adjusted incidence ratio (aIR) and adjusted relative risk (aRR). Borriana COVID-19 cohort 2020.

| Variables                  | Return to the Usual Health |                  | p-Value |
|----------------------------|-----------------------------|------------------|---------|
|                            | aIR (%)                     | aRR (95% CI)     |         |
| Sex 2                      |                             |                  |         |
| Female                     | 79.5                        | 1.00             | 0.014   |
| Male                       | 87.9                        | 1.11 (1.02–1.20) |         |
| Age-groups (years) 3       |                             |                  |         |
| 0–34                       | 88.9                        | 1.14 (1.05–1.24) | 0.002   |
| 35 and above               | 78.0                        | 1.00             |         |
| ABO blood group 4          |                             |                  |         |
| O                          | 86.7                        | 1.00             |         |
| A                          | 81.0                        | 0.93 (0.86–1.01) | 0.094   |
| B                          | 75.7                        | 0.87 (0.73–1.04) | 0.128   |
| AB                         | 100.0                       | 1.15 (1.09–1.21) | 0.000   |

1 CI, confidence interval; 2 Adjusted for age ABO blood group; 3 Adjusted for sex ABO blood group; 4 Adjusted for age sex; 5 Adjusted for sex ABO blood group occupation lifestyle obesity; 6 Adjusted for age ABO blood group occupation lifestyle obesity; 7 Adjusted for age ABO blood group occupation lifestyle obesity; 8 Adjusted for age ABO blood group occupation lifestyle obesity; 9 Adjusted for age sex ABO blood group occupation lifestyle obesity; 10 Adjusted for age sex ABO blood group occupation lifestyle obesity information; 11 MGEs, mass gathering events; 12 Adjusted for age ABO blood group chronic disease occupation obesity other COVID-19 exposures; 13 Adjusted for age ABO blood group chronic disease occupation obesity other COVID-19 exposures; 14 Adjusted for age sex ABO blood group chronic disease lifestyle occupation obesity other COVID-19 exposures; 15 Adjusted for age sex ABO blood group chronic disease lifestyle occupation obesity other COVID-19 exposures; 16 Adjusted for age sex ABO blood group chronic disease lifestyle occupation obesity.
Table 8. Cont.

| Variables                        | Return to the Usual Health | \( \text{aIR} \) (%) | \( \text{aRR (95\% CI)} \) | \( p \)-Value |
|----------------------------------|---------------------------|----------------------|-----------------------------|--------------|
| Occupations                     |                           |                      |                             |              |
| I–II \(^{5}\)                   | 86.2                      | 1.05 (0.97–1.14)     | 0.219                       |              |
| III–VI                          | 81.9                      | 1.00                 |                             |              |
| Chronic disease                  |                           |                      |                             |              |
| Yes                             | 82.3                      | 1.00                 |                             |              |
| No                              | 85.0                      | 1.03 (0.95–1.12)     | 0.449                       |              |
| No-smoking \(^{7}\)            | 84.0                      | 1.03 (0.92–1.16)     | 0.565                       |              |
| Ex-smoking                      | 81.0                      | 1.00                 |                             |              |
| Current smoking                 | 87.0                      | 1.08 (0.94–1.23)     | 0.266                       |              |
| Alcohol consumption             |                           |                      |                             |              |
| Yes                             | 82.6                      | 1.00                 |                             | 0.737        |
| No                              | 84.0                      | 1.02 (0.92–1.12)     |                             |              |
| Physical exercise               |                           |                      |                             |              |
| Yes                             | 82.0                      | 1.00                 |                             |              |
| No                              | 82.6                      | 1.00 (0.92–1.08)     | 0.920                       |              |
| Body Mass Index (BMI) (kg/m\(^2\)) \(^{10}\) |                           |                      |                             |              |
| BMI \( \geq 30.0 \) (Obesity)    | 80.0                      | 1.00                 |                             | 0.659        |
| BMI < 30                        | 82.4                      | 1.03 (0.85–1.11)     |                             |              |
| Observe a person with a cough at MGEs \(^{11,12}\) |                           |                      |                             |              |
| Yes                             | 78.9                      | 1.00                 |                             | 0.146        |
| No                              | 85.1                      | 1.08 (0.97–1.19)     |                             |              |
| Contact with COVID-19 patient \(^{13}\) |                           |                      |                             |              |
| Yes                             | 81.6                      | 1.00                 |                             | 0.000        |
| No                              | 94.0                      | 1.15 (1.06–1.25)     |                             |              |
| Family with COVID-19 patient \(^{14}\) |                           |                      |                             |              |
| Yes                             | 81.8                      | 1.00                 |                             | 0.389        |
| No                              | 84.8                      | 1.04 (0.95–1.13)     |                             |              |
| Attendance MGEs \( \geq 2 \) \(^{15}\) |                           |                      |                             |              |
| Yes                             | 82.0                      | 1.00                 |                             | 0.194        |
| No                              | 86.7                      | 1.07 (0.97–1.15)     |                             | 0.056        |
| At least a COVID-19 exposure \(^{16}\) |                           |                      |                             |              |
| Yes                             | 82.4                      | 1.00                 |                             |              |
| No                              | 91.1                      | 1.11 (0.99–1.22)     |                             |              |

\(^{1}\) CI, confidence interval; \(^{2}\) Adjusted for age ABO blood group; \(^{3}\) Adjusted for sex ABO blood group; \(^{4}\) Adjusted for age sex; \(^{5}\) Adjusted for age ABO blood group occupation lifestyle obesity; \(^{6}\) Adjusted for age sex ABO blood group occupation lifestyle obesity; \(^{7}\) Adjusted for age sex ABO blood group occupation lifestyle obesity information; \(^{8}\) Adjusted for age sex ABO blood group occupation lifestyle obesity; \(^{9}\) Adjusted for age sex ABO blood group occupation lifestyle obesity information; \(^{10}\) Adjusted age sex ABO blood group occupation lifestyle obesity other COVID-19 exposures; \(^{11}\) Adjusted for age sex ABO blood group chronic disease occupation obesity other COVID-19 exposures; \(^{12}\) Adjusted for age sex ABO blood group chronic disease occupation obesity other COVID-19 exposures; \(^{13}\) Adjusted for age sex ABO blood group chronic disease occupation obesity other COVID-19 exposures; \(^{14}\) Adjusted for age sex ABO blood group chronic disease occupation obesity other COVID-19 exposures; \(^{15}\) Adjusted for age sex ABO blood group chronic disease occupation obesity other COVID-19 exposures; \(^{16}\) Adjusted for age sex ABO blood group chronic disease occupation obesity.

4. Discussion

Our results suggest that a third of COVID-19 patients with mild illness experienced post-COVID-19 symptoms six months after the acute episode. The most frequent symptoms were loss of hair, fatigue, and loss of smell or taste. Acute symptoms of illness, female sex and elder age were associated with complications, and a less frequent recovery and return to usual health. As highlighted findings of our study, several exposures to COVID-19, including contact with a COVID-19 patient, attendance to two or more MGEs, and observing a person with a cough at MEGs, were risk factors of complications. On the other hand, lower COVID-19 exposures were associated with better recovery and return to the usual
health. These results are in line with other studies that found COVID-19 exposures were associated with post-traumatic stress symptoms of COVID-19 patients, compatible with LCS [43–45].

Complications of COVID-19 have been observed in many prospective cohort studies indicating the importance of a follow-up of COVID-19 patients [19,46–48]. In general, the frequency and severity of these complications or “sequelae” are associated with acute COVID-19 illness [4,31,49], and our results are consistent with these studies, these being hair loss, fatigue, and loss of smell or taste such as more frequent reported persistent symptoms in a multi-system affection [21,46,50–53]. Considering that our cohort had few hospitalized patients, the incidence of complications was lower in comparison with other cohort studies [49,51,52]. Recovery and return to the usual health were higher than those found by studies in hospitalized and non-hospitalized patients, and medical consultation was lower [54,55]. Soraas and co-authors 2021 [56] analyzed a cohort of non-hospitalized COVID-19 patients, and found 36% reported worse health status one year after illness. Persistent symptoms in cohorts of non-hospitalized patients presented large variations in this percentage, ranging from 20% to 61%, possible due to differences in the duration of follow-up, age and sex distributions, and sample sizes [57,58].

Several symptoms during acute illness were predictive of the post-COVID-19 persistence of symptoms, including weakness, skin lesions, loss of smell or taste, headache, and more of five acute symptoms, in line with cohort studies of non-hospitalized patients [31,51,56,59], but not others [60]. In a study in Norway, fatigue was present in 46% of non-hospitalized COVID-19 patients after a mean of four months; persistence of fatigue was associated with female sex, high numbers of symptoms in the acute illness, and confusion [61]. In addition, dyspnea increased the possibility of post-COVID-19 persistent symptoms and poor health recovery.

We found that females and elder patients experienced a higher frequency of post-COVID-19 symptoms compared with males and young individuals, as has been found in several studies [19,22,31,49,51,61]. The highest incidence of symptoms in females is not well understood and could be associated with the immune viral response [53,56]. Older age can worsen the outcome considering the inflammatory and immunodeficiency state of aging [61–63]. This poor recovery could also be associated with a more frequent severe course of the disease, probably more COVID-19 exposures, and a post-viral disease syndrome which could increase with age [64].

Another associated factor with persistent symptoms was the B blood group compared to the O blood group. A more severe course of COVID-19 disease in the B-group has been described including thrombotic complications [65–67]. The causes of the B-group having more complications compared to the O-group are unknown. Some studies have found that the O-group presents more resistance to some infectious diseases [68], higher physiologic capacity [69], low levels of SARS-CoV-2 IgG compared to non-O groups [70], and some protection from the anti-A/anti-B presence and furin cleavage [71]. In our study [34] the persistence of SARS-CoV-2 antibodies was lower in the O-group, and it has been found that B-group presented higher SARS-CoV-2 neutralizing antibody titers than the other ABO [72].

Current smoking status was associated with more complications, but it was not associated with health recovery and return to the usual health. In some studies, current smoking is a risk factor of illness severity, but there are different results with respect to complications [56,59,73–76]. However, the incidence of COVID-19 in current smokers is lower than in non-smokers [77].

We have not observed an association between BMI, obesity, regular exercise, or alcohol consumption and post-COVID-19 symptoms, in contrast with other studies [31,53]. In addition, high levels of anti-SARS-CoV-2 antibodies or their increase between June 2020 and October 2020 were not associated with complications, recovery, and return to the usual health [33], contrary to other studies [25,28,57]. However, attendance of MGEs, observing a person with a cough at MGEs, and contact with a COVID-19 patient were associated
with complications, inferior recovery, and less frequent return to usual health. All of
the above highlights the importance of intensity of COVID-19 exposure, duration, viral
load, and the place where the exposure occurred [78–81]. In experimental models, the
differences between the persistence of virus infection and the quantity of inoculum have
been found [82].

Our study has some strengths such as its prospective design, a population-based ap-
proach, a high participation rate, a method to explore potential confounding variables [37],
and the use of multivariate analysis in order to estimate adjusted risk factors for different
variables. However, these results could be more accurate. In addition, we studied not only
complications, but also health recovery and return to a usual state of health.

The study limitations include the use of a questionnaire to ascertain reported compli-
cations and symptoms of post-COVID-19 disease, with no medical examination of patients.
As a consequence, we cannot exclude information bias even if the questionnaires were
administered by physicians and nurses. Most of the patients suffered a mild COVID-19
illness, and the participant population is not representative of severe COVID-19 disease.
We cannot discard a residual confounding despite the analysis. COVID-19 is a new dis-
ease and some unknown variables not-collected in our study could have an impact on
our observations.

The causes of LCS are unknown, but some aspects could be considered, including
viral persistence, post-infectious myalgic encephalomyelitis/chronic fatigue syndrome,
metabolism alteration, disproportionate autoimmunity, pathological inflammation, disrup-
tion of the autonomic nervous system, post-traumatic stress, underlying chronic disease,
damage to the lungs, brain, heart, kidney, and other organs [5,17,18,26,83–86].

Considering the high incidence of persistence of COVID-19 related symptomatology
found after COVID-19 infections, some points should be addressed in order to improve
the prevention and management of the LCS, such as the medical follow-up of LCS pa-
tients to establish their natural history, determine laboratory tests needed, validate func-
tional scales, accrue more information of potential risk factors, and apply appropriate
therapies [22,59,84,87,88]. Our prospective design and the population-based approach
have advantages in obtaining results with less bias than other designs.

5. Conclusions

Despite a majority of mild illness, a third of patients presented persistent symptoms
compatible with the LCS, and several risk factors were found. An active medical follow-up
of post-COVID-19 patients must be implemented.

Author Contributions: Conceptualization, S.D.-M., A.A.-P., M.R.P.-S., L.G.-L., D.J.-S., L.A.-E., U.C.-A., S.F.-R. and M.S.-U.; methodology, A.A.-P., S.D.-M., J.P.-B., P.V.-U., M.L.-P., A.D.R.-G., S.F.-R., M.S.-U., G.F.-A., L.A.-E., G.B.-M., U.C.-A., C.D.-B. and M.M.-B.; software A.A.-P., M.R.P.-S., J.P.-B. and M.C.L.-D.; validation, J.P.-B., C.N.-R. and M.R.P.-S.; formal analysis, M.R.P.-S., A.A.-P., J.P.-B. and S.D.-M.; investigation, S.D.-M., M.R.P.-S., P.V.-U., M.L.-P., A.D.R.-G., S.F.-R., G.F.-A., M.S.-U., L.A.-E., G.B.-M., B.C.-F., U.C.-A., C.D.-B., M.F.-C., L.G.-L., D.J.-S., M.C.L.-D., M.D.L.-V., M.M.-B., C.N.-R., R.R.-P. and S.V.-L.; resources, S.D.-M., G.F.-A., G.B.-M., B.C.-F., M.F.-C., L.G.-L., M.C.L.-D., M.D.L.-V., M.L.-P., C.N.-R., R.R.-P. and S.V.-L.; data curation, A.A.-P., J.P.-B., P.V.-U., M.L.-P., A.D.R.-G. and M.R.P.-S.; writing original draft preparation, A.A.-P., J.P.-B., M.R.P.-S., M.C.L.-D., S.D.-M. and S.F.-R.; writing—review and editing, J.P.-B., A.A.-P., S.D.-M., U.C.-A., M.F.-C. and M.C.L.-D.; visualization, J.P.-B., D.J.-S., L.A.-E. and L.G.-L.; supervision M.R.P.-S., M.C.L.-D.; project administration, S.D.-M., A.A.-P., M.C.L.-D. and G.F.-A.; funding acquisition, S.D.-M., M.C.L.-D. and A.A.-P. All authors have
read and agreed to the published version of the manuscript.

Funding: This research received no external funding.
Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki. The study was part of the public health surveillance as a prolongation of the COVID-19 outbreak in the Falles festival in Borriana control measures, which was exempted from Ethics Review Board approval’s protocol according to the Spanish legislation and regulations, including (33) the General Law of Health, (34) the Law of Cohesion and Quality of the National System of Health, and (35) the Law General of Public Health. The study was approved by the director of the Public Health Center of Castellon and the management of the Health Department of La Plana. In addition, (36) the cohort was following to respond to a new disease, the COVID-19 pandemic.

Informed Consent Statement: All participants or the parents of minors provided the informed written consent to be included in the study.

Data Availability Statement: Data of the study can be consulted if the authors are requested. Dataset: borrianaacohort.dta.

Acknowledgments: We thank the participants of the cohort and the Borriana’s Falles organization for the support that made it possible to perform this study. In addition, we appreciate the assistance and support of Roser Blasco-Gari, Helena Buj-Jorda, Israel Borras-Acosta, Lucia Castell-Agusti, Mercedes De Francia-Valero, Maria Doménech-Molinos, Marc Garcia, Maria Gil-Fortuño, Elena Grañana-Toran, Noelia Hernández-Perez, Laura Lopez-Diago, Salvador Martinez-Farra, Sara Moner-Marin, Silvia Pesudo-Calatayud, Lara Sabater-Hernández, Maria Luisa Salve-Martinez, Irene Suarez-Linares, Juan José Ventura-Buchardo, and Alberto Yagüe-Muñoz to carry out the study.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Sridhar, S.; Nicholls, J. Pathophysiology of infection with SARS-CoV-2-What is known and what remains a mystery. Respirology 2021, 26, 652–665. [CrossRef] [PubMed]
2. Van Damme, W.; Dahake, R.; Delamou, A.; Ingelbeen, B.; Wouters, E.; Vanham, G.; van de Pas, R.; Dossou, J.P.; Ir; P.; Abimbola, S.; et al. The COVID-19 pandemic: Diverse contexts; different epidemics-how and why? BMJ Glob. Health 2020, 5, e003098. [CrossRef]
3. Salamanna, F.; Veronesi, F.; Martini, L.; Landini, M.P.; Fini, M. Post-COVID-19 Syndrome: The persistent symptoms at the post-viral stage of the disease: A systematic review of the current data. Front. Med. Lausanne 2021, 8, 653516. [CrossRef] [PubMed]
4. Cairoli, E. ¿De qué hablamos cuando hablamos de post-COVID-19? Rev. Clin. Esp. 2021, 221, 614–616. [CrossRef] [PubMed]
5. Carod-Artal, F.J. Post-COVID-19 syndrome: Epidemiology, diagnostic criteria and pathogenic mechanisms involved. Rev. Neurol. 2021, 72, 384–396.
6. Shah, W.; Hillman, T.; Playford, E.D.; Hishmeh, L. Managing the long term effects of COVID-19: Summary of NICE, SIGN, and RCGP rapid guideline. BMJ 2021, 372, n136. [CrossRef]
7. National Institute for Health and Care Excellence. COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19. Available online: https://www.nice.org.uk/guidance/ng188 (accessed on 12 September 2021).
8. Greenhalgh, T.; Knight, M.; A’Court, C.; Buxton, M.; Husain, I. Management of post-acute COVID-19 in primary care. BMJ 2020, 370, m3026. [CrossRef]
9. Shanbehzadeh, S.; Tavahomi, M.; Zanjari, N.; Ebrahimi-Takamjani, I.; Amiri-Arimi, S. Physical and mental health complications post-COVID-19: Scoping review. J. Psychosom. Res. 2021, 147, 110525. [CrossRef]
10. Sonnweber, T.; Sahanic, S.; Pizzini, A.; Luger, A.; Schwabl, C.; Sonnweber, B.; Kurz, K.; Koppelstätter, S.; Haschka, D.; Petzer, V.; et al. Cardiopulmonary recovery after COVID-19: An observational prospective multicentre trial. Eur. Respir. J. 2021, 57, 2003481. [CrossRef]
11. Starace, M.; Iorizzo, M.; Sechi, A.; Alessandrini, A.M.; Carpanese, M.; Bruni, F.; Vara, G.; Apalla, Z.; Asz-Sigall, D.; Barruscotti, S.; et al. Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management. JAAD Int. 2021, 5, 11–18. [CrossRef]
12. Zarei, M.; Bose, D.; Nouri-Vaskeh, M.; Tajiknia, V.; Zand, R.; Ghasemi, M. Long-term side effects and lingering symptoms post COVID-19 recovery. Rev. Med. Virol. 2021, e2289. [CrossRef]
13. Cozzi, G.; Amaddeo, A.; Barbi, E. Post-COVID syndrome: Turning convalescence into illness? Lancet Reg. Health Eur. 2021, 7, 100163. [CrossRef] [PubMed]
14. Soriano, J.B.; Murthy, S.; Marshall, J.C.; Relan, P.; Diaz, J.V.; WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2021. [CrossRef]
15. Akbarialiabad, H.; Taghiri, M.H.; Abdollahi, A.; Ghahramani, N.; Kumar, M.; Paydar, S.; Razani, B.; Mwangi, J.; Asadi-Pooya, A.A.; Malekmakan, L.; et al. Long COVID, a comprehensive systematic scoping review. Infection 2021, 49, 1163–1186. [CrossRef]
16. Amenta, E.M.; Spallone, A.; Rodriguez-Barradas, M.C.; El Sahly, H.M.; Atmar, R.L.; Kulkarni, P.A. Postacute COVID-19: An overview and approach to classification. Open Forum Infect. Dis. 2020, 7, ofaa509. [CrossRef] [PubMed]
17. Miller, A. COVID-19: Not just an acute illness. Trends Urol. Men’s Health 2020, 11, 17–19. [CrossRef]
18. Poenaru, S.; Abdallah, S.J.; Corrales-Medina, V.; Cowan, J. COVID-19 and post-infectious myalgic encephalomyelitis/chronic fatigue syndrome: A narrative review. *Ther. Adv. Infect. Dis.* 2021, 8, 20499361211009385. [CrossRef] [PubMed]

19. Sigfrid, L.; Drake, T.M.; Pauley, E.; Jessudason, E.C.; Olliaro, P.; Lim, W.S.; Gillesen, A.; Berry, C.; Lowe, D.J.; McPeake, J.; et al. Long covid in adults discharged from UK hospitals after COVID-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. *Lancet Reg. Health Eur.* 2021, 8, 100186. [CrossRef]

20. Nasserie, T.; Hittle, M.; Goodman, S.N. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: A systematic review. *JAMA Netw. Open* 2021, 4, e2111417. [CrossRef]

21. Iqbal, F.M.; Lam, K.; Sounderajah, V.; Clarke, J.M.; Ashrafian, H.; Darzi, A. Characteristics and predictors of acute and chronic post-COVID syndrome: A systematic review and meta-analysis. *E Clinical Medicine* 2021, 36, 100899. [CrossRef]

22. Yong, S.J. Long COVID or post-COVID-19 syndrome: Putative pathophysiology, risk factors, and treatments. *Infec. Dis. 2021, 53, 737–754.* [CrossRef] [PubMed]

23. Carfì, A.; Bernabei, R.; Landi, F.; Gemelli against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients after Acute COVID-19. *JAMA 2020, 324, 603–605.* [CrossRef] [PubMed]

24. Osikowicz, B.; Erinoso, O.; Odusola, A.O.; Thomas, B.; Adeyemi, O.; Bowale, A.; Adejumo, O.; Falana, A.; Abdus-Salam, I.; et al. ‘Long COVID’. Persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria. *BMC Infect. Dis. 2021, 21, 304.* [CrossRef] [PubMed]

25. Peghin, M.; Palese, A.; Venturini, M.; De Martino, M.; Gerussi, V.; Graziano, E.; Bontempo, G.; Marrella, F.; Tommasini, A.; Fabris, M.; et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. *Clin. Microbiol. Infect. 2021, 27, 1507–1513.* [CrossRef] [PubMed]

26. Korompoki, E.; Gavriatopoulou, M.; Hicklen, R.S.; Ntanasis-Stathopoulos, I.; Kastritis, E.; Fiotou, D.; Stamatopoulous, K.; Terpos, E.; Kotanidou, A.; Hagberg, C.A.M.; et al. Epidemiology and organ specific sequelae of post-acute COVID-19: A narrative review. *J. Infect. 2021, 83, 1–16.* [CrossRef]

27. Paderno, A.; Mattavelli, D.; Rampinelli, V.; Grammatica, A.; Raffetti, E.; Tomasoni, M.; Gualtieri, T.; Taboni, S.; Zorzi, S.; Del Bon, F.; et al. Olfactory and gustatory outcomes in COVID-19: A prospective evaluation in nonhospitalized subjects. *Otologyngol. Head Neck Surg. 2020, 163, 1144–1149.* [CrossRef] [PubMed]

28. Horton, D.B.; Barrett, E.S.; Roy, J.; Gennaro, M.L.; Andrews, T.; Greenberg, P.; Bruiners, N.; Datta, P.; Ukey, R.; Velusamy, S.K.; et al. Determinants and dynamics of SARS-CoV-2 infection in a diverse population: 6-month evaluation of a prospective cohort study. *J. Infect. Dis. 2021, 224, 1345–1356.* [CrossRef]

29. Zayet, S.; Zahra, H.; Royer, P.Y.; Tipirdamaz, C.; Mercier, J.; Gendrin, V.; Lepiller, Q.; Marty-Quinternet, S.; Osman, M.; Belleki, N.; et al. Post-COVID-19 Syndrome: Nine months after SARS-CoV-2 infection in a cohort of 354 patients: Data from the first wave of COVID-19 in Nord Franche-Comté Hospital, France. *Microorganisms 2021, 9, 1719.* [CrossRef]

30. Ayoubkhani, D.; Khunti, K.; Nafilyan, V.; Maddox, T.; Humberstone, B.; Diamond, I.; Banerjee, A. Post-covid syndrome in individuals admitted to hospital with COVID-19: Retrospective cohort study. *BMJ 2021, 372, n693.* [CrossRef] [PubMed]

31. Sudre, C.H.; Murray, B.; Varsavsky, T.; Graham, M.S.; Penfold, R.S.; Bowyer, R.C.; Pujol, J.C.; Klaser, K.; Antonelli, M.; Canas, L.S.; et al. Attributes and predictors of long COVID. *Int. J. Environ. Res. Public Health 2021, 18, 10039.* [CrossRef]

32. Doménech-Montoliu, S.; Pac-Sa, M.R.; Vidal-Utrillas, P.; Latorre-Poveda, M.; Del Rio-González, A.; Ferrando-Rubert, S.; Ferrer-Abad, G.; Sánchez-Urbano, M.; Aparisi-Esteve, L.; Badenes-Marques, G.; et al. Mass gathering events and COVID-19 transmission in Borriana (Spain): A retrospective cohort study. *PLoS ONE 2021, 16, e0256747.* [CrossRef]

33. Doménech-Montoliu, S.; Puig-Barberà, J.; Pac-Sa, M.R.; Vidal-Utrillas, P.; Latorre-Poveda, M.; Del Rio-González, A.; Ferrando-Rubert, S.; Ferrer-Abad, G.; Sánchez-Urbano, M.; Aparisi-Esteve, L.; et al. Persistence of anti-SARS-CoV-2 antibodies six months after infection in an outbreak with five hundred COVID-19 cases in Borriana (Spain): A prospective cohort study. *COVID 2021, 1, 71–82.* [CrossRef]

34. Doménech-Montoliu, S.; Puig-Barberà, J.; Pac-Sa, M.R.; Vidal-Utrillas, P.; Latorre-Poveda, M.; Del Rio-González, A.; Ferrando-Rubert, S.; Ferrer-Abad, G.; Sánchez-Urbano, M.; Aparisi-Esteve, L.; et al. ABO blood groups and the incidence of complications in COVID-19 patients: A population-based prospective cohort study. *Int. J. Environ. Res. Public Health 2021, 18, 10039.* [CrossRef] [PubMed]

35. Greenland, S.; Pearl, J.; Robins, J.M. Causal diagrams for epidemiologic research. *Epidemiology 1999, 10, 37–48.* [CrossRef]

36. Teixidó, J.; van der Zander, B.; Gilthorpe, M.S.; Liskiewicz, M.; Ellison, G.T. Robust causal inference using directed acyclic graphs: The R package ‘dagitty’. *Int. J. Epidemiol.* 2016, 45, 1887–1894. [CrossRef]

37. Tennant, P.W.G.; Murray, E.J.; Arnold, K.F.; Berrie, L.; Fox, M.P.; Gadd, S.C.; Harrison, W.J.; Keeble, C.; Ranker, L.R.; Teixidó, J.; et al. Use of directed acyclic graphs (DAGs) to identify confounders in applied health research: Review and recommendations. *Int. J. Epidemiol. 2021, 50, 620–632.* [CrossRef]

38. Robins, J.M.; Hernán, M.A.; Brumback, B. Marginal structural models and causal inference in epidemiology. *Epidemiology 2000, 11, 550–560.* [CrossRef]

39. Ley 14/1986, de 25 de Abril, General de Sanidad (Law General of Health). Available online: https://www.boe.es/eli/es/1/1986/04/25/14/con (accessed on 2 August 2021). (In Spanish)
40. Ley 16/2003, de 28 de Mayo, de Cohesión y Calidad del Sistema Nacional de Salud. (Law of Cohesion and Quality of the National System of Health). Available online: https://www.boe.es/eli/es/1/2003/05/28/16 (accessed on 2 August 2021). (In Spanish)

41. Ley 33/2011, de 4 de Octubre, General de Salud Pública (Law General of Public Health). Available online: https://www.boe.es/eli/es/1/2011/10/04/33/con (accessed on 2 August 2021). (In Spanish)

42. Ministry of Health Agreed in the Interterritorial Council of the National Health System. Early Response Plan in a COVID-19 Pandemic Control Scenario. 2020. Available online: https://www.sanidad.gob.es/profesionales/saludPublica/cayes/alertasActual/nCov/documentos/COVID19_Plan_de_resposta_temprana_escenario_control.pdf (accessed on 2 August 2021). (In Spanish)

43. Boyraz, G.; Legros, D.N. Coronavirus disease (COVID-19) and traumatic stress: Probable risk factors and correlates of posttraumatic stress disorder. J. Loss Trauma 2020, 25, 503–522. [CrossRef]

44. Sun, L.; Sun, Z.; Wu, L.; Zhu, Z.; Zhang, F.; Shang, Z.; Jia, Y.; Gu, J.; Zhou, Y.; Wang, Y.; et al. Prevalence and risk factors for acute posttraumatic stress disorder during the COVID-19 outbreak. J. Affect. Disord. 2021, 15, 123–129. [CrossRef]

45. Jiang, H.; Nan, J.; Lv, Z.; Yang, J. Psychological impacts of the COVID-19 epidemic on Chinese people: Exposure, post-traumatic stress symptom, and emotion regulation. Asian Pac. J. Trop. Med. 2020, 10, 252–259.

46. Huang, C.; Huang, L.; Wang, Y.; Li, X.; Ren, L.; Gu, X.; Kang, L.; Guo, L.; Liu, M.; Zhou, X.; et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet 2020, 397, 220–232. [CrossRef]

47. Bell, M.L.; Catalifano, C.J.; Farland, L.V.; Ernst, K.C.; Jacobs, E.T.; Klimendić, Y.C.; Jahn, M.; Pogreba-Brown, K. Post-acute sequelae of COVID-19 in a non-hospitalized cohort: Results from the Arizona CoVHORT. PloS ONE 2021, 16, e0254347. [CrossRef]

48. Daugherty, S.E.; Guo, Y.; Heath, K.; Dasmariñas, M.C.; Jubilo, K.G.; Samranvedhya, J.; Lipsitch, M.; Cohen, K. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: Retrospective cohort study. BMJ 2021, 373, n1098. [CrossRef] [PubMed]

49. Mahmud, R.; Rahman, M.M.; Rassel, M.A.; Monayem, F.B.; Sayeed, S.K.J.B.; Islam, M.S.; Islam, M.M. Post-COVID-19 syndrome among symptomatic COVID-19 patients: A prospective cohort study in a tertiary care center of Bangladesh. PloS ONE 2021, 16, e0249644. [CrossRef]

50. Xiong, Q.; Xu, M.; Li, J.; Liu, Y.; Zhang, J.; Xu, Y.; Dong, W. Clinical sequelae of COVID-19 survivors in Wuhan, China: A single-centre longitudinal study. Clin. Microbiol. Infect. 2021, 27, 89–95. [CrossRef]

51. Augustin, M.; Schommers, P.; Stecher, M.; Dewald, F.; Gieselmann, L.; Gruehl, H.; Horn, C.; Vanshylla, K.; Cristanziano, V.D.; Osebold, L.; et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: A longitudinal prospective cohort study. Lancet Reg. Health Eur. 2021, 6, 100122. [CrossRef] [PubMed]

52. Moreno-Pérez, O.; Merino, E.; Leon-Ramirez, J.M.; Andres, M.; Ramos, J.M.; Arenas-Jiménez, J.; Asensio, S.; Sanchez, R.; Ruiz-Torregrosa, P.; Galan, I.; et al. Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study. J. Infect. 2021, 82, 378–383. [CrossRef]

53. Bliddal, S.; Banasik, K.; Pedersen, O.B.; Nissen, J.; Cantwell, L.; Schwinn, M.; Tulstrup, M.; Westergaard, D.; Ullum, H.; Brunak, S.; et al. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. Sci. Rep. 2021, 11, 13153. [CrossRef]

54. Tenforde, M.W.; Kim, S.S.; Lindsell, X.J.; Billig Rose, E.; Shapiro, N.I.; Files, D.C.; Gibbs, K.W.; Erickson, H.L.; Steingrub, J.S.; Smithline, H.A.; et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network—United States, March–June 2020. MMWR Morb. Mortal. Wkly. Rep. 2020, 69, 993–998. [CrossRef] [PubMed]

55. Menges, D.; Ballouz, T.; Anagnostopoulos, A.; Aschmann, H.E.; Domenghino, A.; Fehr, J.S.; Puhan, M.A. Burden of post-acute COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study. PloS ONE 2021, 16, e0254523. [CrossRef]

56. Søraas, A.; Kalleberg, K.T.; Dahl, J.A.; Søraas, C.L.; Brokstad, K.A.; Myklebust, T.A.; Axelsen, E.; Lind, A.; Bøvre-Jensen, R.; Jørgensen, S.B.; Istre, M.S.; et al. Persisting symptoms three to eight months after non-hospitalized sequelae of COVID-19, a prospective cohort study. PloS ONE 2021, 16, e0256142. [CrossRef]

57. Blomberg, B.; Mohn, K.G.; Brokstad, K.A.; Zhou, F.; Linchausen, D.W.; Hansen, B.A.; Larøy, S.; Önyango, T.B.; Kuwelker, K.; Savik, M.; et al. Long COVID in a prospective cohort of home-isolated patients. Nat. Med. 2021, 27, 1607–1613. [CrossRef]

58. Saad, N.J.; Moeck, F.; Steitz, F.; Muralja, L.; Bärnighausen, T.; Zoller, T.; Pörtner, K.; Muller, N. A longitudinal study on symptom duration and 60-day clinical course in non-hospitalised COVID-19 cases in Berlin, Germany, March to May, 2020. Eurosurveillance 2021, 26, 2001757. [CrossRef] [PubMed]

59. Jacobson, K.B.; Rao, M.; Bonilla, H.; Subramanian, A.; Hack, I.; Madrigal, M.; Singh, U.; Jagannathan, P.; Grant, P. Patients with uncomplicated coronavirus disease (COVID-19) have long-term persistent symptoms and functional impairment similar to patients with severe COVID-19: A cautionary tale during a global pandemic. Clin. Infect. Dis. 2021, 73, e826–e829. [CrossRef]

60. Anaya, J.M.; Rojas, M.; Salinas, M.L.; Rodriguez, Y.; Roa, G.; Lozano, M.; Rodriguez-Jiménez, M.; Montoya, N.; Zapata, E.; Post-COVID Study Group; et al. Post-COVID syndrome. A case series and comprehensive review. Autoimmun. Rev. 2021, 20, 102947. [CrossRef]

61. Stavem, K.; Ghanima, W.; Olsen, M.K.; Gilboe, H.M.; Einvik, G. Prevalence and determinants of fatigue after COVID-19 in non-hospitalized subjects: A population-based study. Int. J. Environ. Res. Public Health 2021, 18, 2030. [CrossRef] [PubMed]

62. Bektas, A.; Schurman, S.H.; Franceschi, C.; Ferrucci, L. A public health perspective of aging: Do hyper-inflammatory syndromes such as COVID-19, SARS, ARDS, cytokine storm syndrome, and post-ICU syndrome accelerate short- and long-term inflammaging? Immun. Ageing 2020, 17, 23. [CrossRef] [PubMed]
63. Tosato, M.; Carfi, A.; Martis, I.; Pais, C.; Cicciarello, F.; Rota, E.; Tritto, M.; Salerno, A.; Zazzara, M.B.; Martone, A.M.; et al. Prevalence and predictors of persistence of COVID-19 symptoms in older adults: A single-center study. J. Am. Med. Dir. Assoc. 2021, 22, 1840–1844. [CrossRef]

64. Chu, L.; Valencia, I.J.; Garvert, D.W.; Montoya, J.G. Onset patterns and course of myalgic encephalomyelitis/Chronic Fatigue Syndrome. Front. Pediatr. 2019, 7, 12. [CrossRef]

65. Zalba Marcos, S.; Antelo, M.L.; Galbete, A.; Etayo, M.; Ongay, E.; Garcia-Erce, J.A. Infection and thrombosis associated with COVID-19: Possible role of the ABO blood group. Med. Clin. Barc. 2020, 155, 340–343. [CrossRef]

66. Ray, J.G.; Schull, M.J.; Vermeulen, M.J.; Park, A.L. Association between ABO and Rh blood groups and SARS-CoV-2 infection or severe COVID-19 illness: A population-based cohort study. Ann. Intern. Med. 2021, 174, 308–315. [CrossRef] [PubMed]

67. Padhi, S.; Suvankar, S.; Dash, D.; Panda, V.K.; Pati, A.; Panigrahi, J.; Panda, A.K. ABO blood group system is associated with COVID-19 mortality: An epidemiological investigation in the Indian population. Transfus. Clin. Biol. 2020, 27, 253–258. [CrossRef]

68. Arend, P. Why blood group A individuals are at risk whereas blood group O individuals are protected from SARS-CoV-2 (COVID-19) infection: A hypothesis regarding how the virus invades the human body via ABO(H) blood group-determining carbohydrates. Immunobiology 2021, 226, 152027. [CrossRef] [PubMed]

69. Groot, H.E.; Villegas Sierra, L.E.; Said, M.A.; Lipsic, E.; Karper, J.C.; van der Harst, P. Genetically determined ABO blood group and its associations with health and disease. Arter. Thromb. Vasc. Biol. 2020, 40, 830–838. [CrossRef]

70. Hayes, C.; Rubenstein, W.; Gibb, D.; Klapper, E.; Tanaka, J.; Pepkowitz, S. Blood group O convalescent plasma donations have significantly lower levels of SARS-CoV-2 IgG antibodies compared to blood group A donations. Transfusion 2021, 61, 2245–2249. [CrossRef] [PubMed]

71. Le Pendu, J.; Breiman, A.; Rocher, J.; Dion, M.; Ruvoën-Clouet, N. ABO blood types and COVID-19: Spurious, Anecdotal, or truly important relationships? A reasoned review of available data. Viruses 2021, 13, 160. [CrossRef]

72. Bloch, E.M.; Patel, E.U.; Marshall, C.; Littlefield, K.; Goel, R.; Grossman, B.J.; Winters, J.L.; Shrestha, R.; Burgess, I.; Laeyendecker, O.; et al. ABO blood group and SARS-CoV-2 antibody response in a convalescent donor population. Vox Sang. 2021, 116, 766–773. [CrossRef] [PubMed]

73. Monteiro, A.C.; Suri, R.; Emeruwa, I.O.; Stretch, R.J.; Cortes-Lopez, R.Y.; Sherman, A.; Lindsay, C.C.; Fulcher, J.A.; Goodman-Meza, D.; Sapru, A.; et al. Obesity and smoking as risk factors for invasive mechanical ventilation in COVID-19: A retrospective, observational cohort study. PLoS ONE 2020, 15, e0238552. [CrossRef]

74. Lowe, K.E.; Zein, J.; Hatipoglu, U.; Attaway, A. Association of smoking and cumulative pack-year exposure with COVID-19 outcomes in the Cleveland Clinic COVID-19 Registry. JAMA Intern. Med. 2021, 181, 709–711. [CrossRef]

75. Yanover, C.; Mizrahi, B.; Kalkstein, N.; Marcus, K.; Akiva, P.; Barer, Y.; Shalev, V.; Chodick, G. What factors increase the risk of complications in SARS-CoV-2-infected patients? A cohort study in a nationwide Israeli health organization. JMIR Public Health Surveill. 2020, 6, e20872. [CrossRef]

76. Khalil, A.; Dhingra, R.; Al-Mulki, J.; Hassoun, M.; Alexis, N. Questioning the sex-specific differences in the association of smoking on the survival rate of hospitalized COVID-19 patients. PLoS ONE 2021, 16, e0255692. [CrossRef]

77. Prinelli, F.; Bianchi, F.; Drago, G.; Ruggieri, S.; Sojic, A.; Jesuthasan, N.; Molinaro, S.; Bastiani, L.; Maggi, S.; Noale, M.; et al. Association between smoking and SARS-CoV-2 infection: Cross-sectional study of the EPICOVID19 internet-based survey. JMIR Public Health Surveill. 2021, 7, e27091. [CrossRef]

78. Calisti, R. SARS-CoV-2 Exposure: High external doses as determinants of higher viral loads and of increased risk for COVID-19. A systematic review of the literature. Epidemiol. Prev. 2020, 44, 152–159. [PubMed]

79. Helle, K.B.; Sadiku, A.; Zelleke, G.M.; Ibrahim, T.B.; Boub, A.; Tsoungui Obama, H.C., Jr.; Appiah, V.; Ngwa, G.A.; Teboh-Ewungkem, M.I.; Schneider, K.A. Is increased mortality by multiple exposures to COVID-19 an overseen factor when aiming for herd immunity? PLoS ONE 2021, 16, e0253758. [CrossRef] [PubMed]

80. Liu, S.; Yuan, H.; Zhang, B.; Li, W.; You, J.; Liu, J.; Zhong, Q.; Zhang, L.; Chen, L.; Li, S.; et al. Comparison of clinical features and CT temporal changes between familial clusters and non-familial patients with COVID-19 pneumonia. Front. Med. Lausanne 2021, 8, 630802. [CrossRef] [PubMed]

81. Trübner, F.; Steigert, L.; Echterdiek, F.; Jung, N.; Schmidt-Hellerau, K.; Zoller, W.G.; Frick, J.S.; Feng, Y.S.; Paul, G. Predictors of COVID-19 in an outpatient fever clinic. PLoS ONE 2021, 16, e0254990. [CrossRef]

82. Fain, B.; Dobrovolsky, H.M. Initial inoculum and the severity of COVID-19: A mathematical modeling study of the dose-response of SARS-CoV-2 Infections. Epidemiology 2020, 1, 5–15. [CrossRef]

83. Gassen, N.C.; Papes, J.; Bajaj, T.; Emanuel, J.; Dethloff, F.; Chua, R.L.; Trimpert, J.; Heinemann, N.; Niemeyer, C.; Weege, F.; et al. SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals. Nat. Commun. 2021, 12, 3818. [CrossRef] [PubMed]

84. Trinkmann, F.; Müller, M.; Reif, A.; Kahn, N.; Kreuter, M.; Trudzinski, F.; Eichinger, M.; Heussel, C.P.; Herth, F.J.F. Residual symptoms and lower lung function in patients recovering from SARS-CoV-2 infection. Eur. Respir. J. 2021, 57, 2003002. [CrossRef]

85. Dani, M.; Dirksen, A.; Taraborrelli, P.; Torocastro, M.; Panagopoulos, D.; Sutton, R.; Lim, P.B. Autonomic dysfunction in ‘long COVID’: Rationale, physiology and management strategies. Clin. Med. Lond. 2021, 21, e63–e67. [CrossRef]
86. Einvik, G.; Dammen, T.; Ghanima, W.; Heir, T.; Stavem, K. Prevalence and risk factors for post-traumatic stress in hospitalized and non-hospitalized COVID-19 Patients. *Int. J. Environ. Res. Public Health* 2021, 18, 2079. [CrossRef] [PubMed]

87. Weidmann, M.D.; Ofori, K.; Rai, A.J. Laboratory biomarkers in the management of patients with COVID-19. *Am. J. Clin. Pathol.* 2021, 155, 333–342. [CrossRef] [PubMed]

88. Machado, F.V.; Meys, R.; Delbressine, J.M.; Vaes, A.W.; Goërtz, Y.M.J.; van Herck, M.; Houben-Wilke, S.; Boon, G.J.A.M.; Barco, S.; Burtin, C.; et al. Construct validity of the Post-COVID-19 Functional Status Scale in adult subjects with COVID-19. *Health Qual. Life Outcomes* 2021, 19, 40. [CrossRef] [PubMed]